GET DAILY SIGNALSTheriva Biologics (TOVX) Stock Drops -18% Over 30 Days Amid Financing Concerns
Key Takeaways
- TOVX shares fell roughly 18% over the last 30 days, declining from about $0.225 to $0.184, as financing and dilution concerns outweighed positive clinical updates.
- The decline reflects the position of a pre-revenue, clinical-stage biotech operating under a going-concern warning with a cash runway guided into the first quarter of 2027.
- Theriva's November 2 sale of its antibiotic-degrading enzyme portfolio to Biossil Labs narrows the company's focus to lead oncology candidate VCN-01.
- A special shareholder meeting set for November 18 seeks to raise authorized shares to 500 million and ratify warrant issuance, heightening dilution risk.
- Publication of VIRAGE Phase 2b results in Nature Medicine showed improved survival, but upside was capped by funding uncertainty.
- For additional detail, explore Theriva Biologics' Price Targets, Earnings, and Forecast pages.
Theriva Biologics (TOVX) Background and Strategic Focus
Theriva Biologics, Inc. is a Rockville, Maryland-based clinical-stage biotechnology company developing therapeutics for cancer and related diseases in areas of high unmet need. Formerly known as Synthetic Biologics, the company rebranded in 2022 and now centers its strategy on an oncolytic adenovirus platform. Its lead candidate, VCN-01 (zabilugene almadenorepvec), is a systemically administered oncolytic adenovirus designed to replicate selectively within tumor cells and degrade the tumor stroma, a barrier that can blunt the effect of chemotherapy and immunotherapy.
VCN-01 has been studied in metastatic pancreatic ductal adenocarcinoma (PDAC), head and neck cancer, ovarian cancer, colorectal cancer, and retinoblastoma. The company has also historically advanced microbiome-focused assets, including SYN-004 (ribaxamase), though it divested this enzyme portfolio in early November 2026. As a micro-cap with a market capitalization of roughly $8 million to $10 million, Theriva is closely followed by investors focused on oncology catalysts, clinical readouts, and balance-sheet risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
TOVX Stock Price Performance: Last 30 Days and Quarter
Over the last 30 days, TOVX declined approximately 18%, moving from a closing price near $0.225 to around $0.184. The move was punctuated by a highly volatile session on November 2, when shares traded as low as roughly $0.14 in pre-market activity before recovering to close at $0.184 on unusually heavy volume exceeding 90 million shares, versus a 65-day average nearer 6.7 million shares.
The quarterly trend has been similarly negative. Over the trailing three-month period, the stock fell roughly 17%, from about $0.223 in early August to the recent $0.184 level. Within that span, TOVX reached a local peak near $0.25 in late August and early September before trending steadily lower through October. In short, both the 30-day and three-month periods show a sustained downward drift driven less by a single event than by persistent financing uncertainty.
Factors Behind the Recent 30-Day Decline
Several verified developments shaped the recent decline. The most consequential was mounting dilution and liquidity pressure. On October 20, Theriva filed a definitive proxy statement scheduling a special shareholder meeting for November 18 to seek authorization to increase its authorized common shares to 500 million and to ratify the potential issuance of up to roughly 16.2 million warrant shares. The proposal signaled the likelihood of future equity financing, a key concern for existing holders of a sub-$1 stock.
The company's balance sheet reinforced that concern. Theriva reported $11.3 million in cash and equivalents as of June 30, 2026, with a runway guided only into the first quarter of 2027, and its filings have disclosed substantial doubt about its ability to continue as a going concern. On November 2, the company announced the sale of its SYN-004 (ribaxamase) and related antibiotic-degrading enzyme portfolio to Biossil Labs for a $350,000 upfront payment plus potential regulatory and sales milestones, a move that consolidates focus on VCN-01 but also underscores the need to conserve capital.
Positive news, including the September 30 publication of VIRAGE Phase 2b data in Nature Medicine showing improved overall and progression-free survival when VCN-01 was added to standard chemotherapy, provided limited sustained support against the financing overhang and broader weakness in pre-revenue biotech equities. From what I see, this financing overhang remains the dominant theme.
Quarterly Performance Drivers and Clinical Progress
The broader three-month narrative reflects a company advancing promising clinical data while struggling to fund the next stage of development. During the quarter, Theriva dosed the first patients in VIRAGE2, a Phase 2a study in Spain evaluating more frequent repeated dosing of VCN-01 in first-line metastatic PDAC, and published its VIRAGE Phase 2b results in a peer-reviewed journal. The U.S. FDA and European regulators had previously agreed with a randomized Phase 3 design using overall survival as the primary endpoint.
However, the company has not secured the financing required to run a pivotal Phase 3 trial, and management has signaled it will pursue development funding or partnerships. The resulting mismatch between a Phase 3-ready asset and limited cash has kept sentiment cautious, allowing the stock to grind lower even as clinical milestones advanced. The divestiture of the enzyme portfolio completes a strategic pivot to a pure-play oncology focus centered entirely on VCN-01. I'm watching this closely as the company narrows its pipeline.
Near-Term Catalysts and Risks to Monitor
Several near-term catalysts could influence TOVX in the coming months. The company's third-quarter 2026 earnings report is expected in mid-November, with investors focused on cash position, runway guidance, and any update on VIRAGE2 enrollment. The November 18 special shareholder meeting will be closely watched, as approval of the share authorization increase could precede future financing transactions that affect the share count.
Longer term, the key milestones are completion of VIRAGE2 enrollment in the second half of 2026 and initial pharmacodynamic and safety data anticipated in the third quarter of 2027. Equally important will be whether Theriva secures a partner, licensing arrangement, or new capital to advance VCN-01 into a pivotal Phase 3 trial. The company's ability to extend its cash runway beyond the first quarter of 2027 remains the central risk factor for the stock.
Exploring AI Tools in My Research Process
In my analysis of volatile names like TOVX, I often turn to automated resources to cross-check patterns and sentiment. One tool I have found useful for this is Tickeron's AI Trading Bots, which offers a range of systematic strategies that can complement fundamental review. These bots cover various styles and timeframes, helping me identify approaches that align with my own risk parameters without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
Momentum Indicator for TOVX turns negative, indicating new downward trend
TOVX saw its Momentum Indicator move below the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 87 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TOVX turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 45 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TOVX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TOVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TOVX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TOVX's RSI Oscillator exited the oversold zone, 32 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 64 of 75 cases where TOVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
TOVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.693) is normal, around the industry mean (3.051). P/E Ratio (0.128) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (23.753) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. TOVX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TOVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement